You are here:

Archived: ranolazine (Ranexa)


Following a full submission

ranolazine (Ranexa) is not recommended for use within NHS Scotland as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).

When added to standard doses of antianginal drugs, ranolazine increased exercise duration at trough drug levels after 12 weeks compared with placebo. However, the effect size was small.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

The licence holder has indicated their intention to resubmit

Drug Details

Drug Name: ranolazine (Ranexa)
SMC Drug ID: 565/09
Manufacturer: A Menarini Pharmaceuticals UK Ltd
Indication: Symptomatic treatment of patients with stable angina pectoris
BNF Category:
Sub Category: 2.6 Nitrates*** calcium-channel blockers*** and other antianginal drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 7 September 2009

Current Advice

IRP 12 November 2012

Archived Advice

Resubmission 16 January 2012
Resubmission 13 December 2010